NewswireTODAY - /newswire/ - Delhi, India, 2009/02/09 - Potential Opportunities - The report analyzes the IV iron market in the context of opportunities it holds for iron drug manufacturers. Further, it analyzes the factors that could drive the growth of IV drugs market in the future.

Iron deficiency anemia or IDA is among one of the top ten most important public health issues, according to the World Health Organization. With approximately one-third of the current global population facing the problem of iron deficiency, more and more people are likely to suffer from a lack of iron in their diet in the near future due to changes in eating habits and rising life expectancy.

Currently, iron supplements used in the context of IDA account for the majority share of the iron-based medicines but this is likely to change with the growing utility of intravenous iron (IV) drugs. Earlier, the IV iron market was mainly achieved in the hemodialysis (HD) setting, but IV iron is likely to be used more in many other therapeutic areas which are highly under-penetrated.

One of the major attractiveness of IV iron especially in regions outside the United States is its pricing and growing number of CKD population. Generally the pricing of IV irons outside the U.S. is lower and the iron market in countries like China is underdeveloped, but growing rapidly, with tremendous potential.

Venofer from Galenica Limited has emerged as the undisputed leader in the IV iron drugs market overtaking the market share of Watson’s InFed and Ferrlecit. Still the whole IV iron market holds immense business opportunities mainly because of increase in the number of haemodialysis patients and limitation in various iron replacement therapies and scope for innovation.

The report broadly includes the following:

1. Iron Deficiency Anemia: An Overview

2. Chronic Kidney Disease (CKD) and IV Iron Products

2.1 Prevalence of CKD
2.2 CKD associated anemia
2.3 Prevalence of CKD associated anemia
2.4 CKD associated anemia - Therapies
2.4.1 Oral Iron Repletion Therapy
2.4.2 Intravenous Iron Infusion Therapy
2.5 Applications of IV iron products in therapeutic areas

3. Global Market for Iron-Based Medicines

4. Intravenous Iron (IV) Drugs: Global Market

5. US Intravenous Iron (IV) Drugs Market

6. Growth Drivers

7. Market Opportunities

8. Competitive Landscape

9. Leading IV Drugs Companies
9.1 Galenica Ltd. (Venofer and Ferinject)
9.2 Watson Pharma (Ferrlecit and InFed)

10. Market Forecast

Tables and Figures

Stages of chronic kidney disease
Prevalence of CKD in the US Population: 1996-2020
US CKD: Patients undergoing Dialysis & receiving Iron Treatment
Global Market of Iron Products: 2003-2007
Market Share of Oral and IV Iron Drugs: 2007
Global IV Iron Market: 2006 & 2007 (Forecast 2008-2010)
Global IV Iron Sales Break-up (In & outside dialysis CKD): 2006 & 2007 (Forecast 2008-2010)
Global IV Iron Sales by Geography: 2007
US CKD Patient Profile
US IV Iron Market: 2006 & 2007 (Forecast 2008-2010)
US Intravenous Iron Market - Share by Brands: 2007
Number of dialysis patients worldwide - Trends (2004-2015)
Prevalence of Diabetes in Five Major Countries: 2000 & 2010
Incidence of ESRD by year (per million population): Major Countries
Prevalence of ESRD by year (per million population): Major Countries
IV Market Potential – Major therapeutic areas
Global Iron Drugs Supplement Market Share: 2006
Global Market Share of leading IV iron drugs players: 2003-07
Global Market Share of Parenteral IV Drugs: 2007
Global IV Iron Market Forecast: 2008-2010
CKD Dialysis & Non Dialysis: Patients receiving Iron Treatment.

Agency / Source: Koncept Analytics

Availability: All Regions (Including Int'l)

Traffic Booster: [/] Quick NewswireToday Visibility Checker

Distribution / Indexing: [+]